| Business Summary | | Exelixis,
Inc.
is
a
biotechnology
company
focused
on
the
discovery
and
validation
of
novel
targets
for
several
major
human
diseases,
and
on
the
discovery
of
potential
new
drug
therapies,
specifically
for
cancer
and
other
proliferative
diseases.
The
Company
is
focused
on
the
life
sciences
industries
and
development
of
proprietary
drugs,
through
its
experience
in
comparative
genomics
and
model
system
genetics.
The
Company
also
develops
proprietary
genetic,
biochemical
and
cell-based
assays
for
use
in
screening
for
potential
targets,
proteins
and
products. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Exelixis,
Inc.
is
a
provider
of
comparative
genomics
and
model
system
genetics
services,
allowing
for
the
identification
and
validation
of
novel
screening
targets
and
proteins
and
their
function
for
the
pharmaceutical,
diagnostic
and
other
industries.
For
the
six
months
ended
6/30/01,
total
revenues
rose
41%
to
$16.3
million.
Net
loss
rose
99%
to
$36.4
million.
Results
reflect
additional
contract
revenues
from
existing
collaborations,
offset
by
increased
staffing. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Stelios Papadopoulos, Ph.D., 52 Chairman | -- | -- | George Scangos, Ph.D., 52 Pres,
CEO, Director | $672K | $680K | Glen Sato, 42 CFO,
VP of Legal Affairs and Sec. | 240K | 169K | Geoffrey Duyk, M.D., Ph.D., 41 Director,
CSO | 443K | 240K | Lloyd Kunimoto, 47 Sr.
VP, Bus. Devel. | 290K | 240K | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|